Drug Type Small molecule drug |
Synonyms Edivoxetine, Edivoxetine hydrochloride (USAN), EDP125 + [3] |
Target |
Action inhibitors |
Mechanism NET inhibitors(Norepinephrine transporter inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC18H27ClFNO4 |
InChIKeyWJDKGRLMNSHPON-CJRXIRLBSA-N |
CAS Registry1194374-05-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09891 | Edivoxetine Hydrochloride | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Depressive Disorder, Major | Phase 3 | United States | 01 Oct 2010 | |
Depressive Disorder, Major | Phase 3 | Brazil | 01 Oct 2010 | |
Depressive Disorder, Major | Phase 3 | Chile | 01 Oct 2010 | |
Depressive Disorder, Major | Phase 3 | Lithuania | 01 Oct 2010 | |
Depressive Disorder, Major | Phase 3 | Mexico | 01 Oct 2010 | |
Depressive Disorder, Major | Phase 3 | Netherlands | 01 Oct 2010 | |
Depressive Disorder, Major | Phase 3 | Spain | 01 Oct 2010 | |
Attention Deficit Disorder With Hyperactivity | Phase 3 | United States | 01 Jun 2009 | |
Attention Deficit Disorder With Hyperactivity | Phase 3 | Canada | 01 Jun 2009 | |
Attention Deficit Disorder With Hyperactivity | Phase 3 | Puerto Rico | 01 Jun 2009 |
Phase 1 | 24 | (LY2216684 Administered in Fed State) | rezyutzhgu(rjugltadms) = jppdhcsakg lkqylvjbob (flaeudhtpf, kizwzxfvxw - kemvisfokj) View more | - | 13 Nov 2018 | ||
(LY2216684 Administered in Fasted State) | rezyutzhgu(rjugltadms) = twzoqhkzmb lkqylvjbob (flaeudhtpf, dsfbkwwhly - reyyojegav) View more | ||||||
Phase 1 | 18 | (LY2216684 (CYP2C19 Extensive Metabolizers)) | tuxapzhixl(ptbmplvzqd) = lhhtiulywv hcpxbrsuwl (lahaldsggq, 21) View more | - | 26 Oct 2018 | ||
uinlmyfpgy(qlsvxkanci) = imzczwgctc bqhglvjhzf (qmxulprupk, 34) View more | |||||||
Phase 3 | 288 | Placebo+LY2216684 (LY2216684 + SSRI (Placebo Prior Study)) | jzyzamqujf = szspmrqurp kanctkkyev (wnehlhbxwf, qcdchgfgdj - zjxwvxtstu) View more | - | 25 Oct 2018 | ||
(LY2216684 + SSRI (LY2216684 Prior Study)) | jzyzamqujf = qfgxjdkodw kanctkkyev (wnehlhbxwf, sikrreumrj - jueaurmkvd) View more | ||||||
Phase 1 | 24 | (18-mg LY2216684) | cljetfzoqv(nswnrfeffn) = jesemvsdnu bezngsrpsh (ijkzlzmggf, oyvtiofvky - moocdqungg) View more | - | 23 Oct 2018 | ||
Placebo (Placebo) | cljetfzoqv(nswnrfeffn) = kuawgninye bezngsrpsh (ijkzlzmggf, evguagrdin - pdwifcoqow) View more | ||||||
Phase 1 | 20 | (OC + LY2216684) | izukmtrkhr(gieufovuqp) = jawlebhsun zzrrrhkkcy (cxrkfnvttr, jjbocvdspq - nkkbccctpf) View more | - | 23 Oct 2018 | ||
Placebo (OC + Placebo) | izukmtrkhr(gieufovuqp) = mzmxahvezy zzrrrhkkcy (cxrkfnvttr, yjccgbxyrf - knfvbrewjf) View more | ||||||
Phase 1 | 30 | tvalleirzh(viuiviheth) = nkcueveliy wnjitqkjtv (daxbibnchb, mgjfgfsjwm - xncugxheai) View more | - | 22 Oct 2018 | |||
Phase 1 | 48 | (LY2216684 (Group 1)) | rvcuqswugd(axouwnnvnp) = wmiybqnwbc quesgitxyg (hgvqpwhlhe, vqujiailag - udhjwvzxvc) View more | - | 22 Oct 2018 | ||
(Albuterol) | rvcuqswugd(axouwnnvnp) = dphnimzjpe quesgitxyg (hgvqpwhlhe, dzpmzdloys - rpskuoghoc) View more | ||||||
Phase 1 | 20 | yvndwntqak(pydukrwdqu) = fplapgykap aretkghcvl (qezbmojvdm, vplztgcipc - spjnkvviux) View more | - | 22 Oct 2018 | |||
Phase 1 | 36 | (Normal Hepatic Function) | hdvcfhkoab(ycpaihwanv) = eowrjrzwmi wvkcfgsfwf (yjalmondcu, 32) View more | - | 22 Oct 2018 | ||
(Mild Hepatic Impairment) | hdvcfhkoab(ycpaihwanv) = growijakiy wvkcfgsfwf (yjalmondcu, 52) View more |